U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939555) titled 'Personalized Antisense Oligonucleotide Therapy for Participants With Progressive Axonal Neuropathy Due to SLC12A6 Mutation' on Nov. 04.

Brief Summary: This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for individual participants with axonal neuropathy due to a mutation in the SLC12A6 gene.

Study Start Date: Sept. 25

Study Type: INTERVENTIONAL

Condition: Progressive Axonal Neuropathy

Intervention: DRUG: nL-SLC12-001

Personalized antisense oligonucleotide

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: n-Lorem Foundation

Published by HT Digital Content Services with per...